Zusammenfassung
Hintergrund
Genetische Aortensyndrome (GAS) sind meist autosomal-dominant erbliche thorakale Aortenaneurysmen, die bereits im jungen Alter zur Ruptur und thorakaler Aortendissektion führen.
Ziel der Arbeit
Wir möchten den Leser mit Prinzipien der genetischen Diagnostik sowie der medikamentösen und chirurgischen Prävention der genetischen Aortensyndrome vertraut machen.
Methoden
Ein Autorenteam, bestehend aus Kardiologe, Gesundheitsökonom, Patientenvertreter, Herzchirurg und Molekulargenetiker, erläutert die aus ihrer Sicht wichtigsten Aspekte zur Genetik und Prävention des genetischen Aortensyndroms.
Ergebnisse
Genetische Aortensyndrome bestehen aus einem breiten Spektrum verschiedener Krankheitsentitäten wie Marfan-Syndrom, Loeys-Dietz-Syndrom und vaskuläres Ehlers-Danlos-Syndrom. Die Diagnostik von genetischen Aortensyndromen basiert auf kombinierter Charakterisierung von Phänotyp und Genotyp. Eine medikamentöse Prävention ist wichtig, obgleich eine Heilung genetischer Aortensyndrome gegenwärtig unwahrscheinlich ist. Das wichtigste Prinzip der Prävention einer thorakalen Aortendissektion ist der prophylaktische Ersatz der Aortenwurzel durch klappenerhaltende Operationstechniken. Prävention inklusive molekulargenetischer Diagnostik ist auch ökonomisch rational.
Diskussion
Optimale prophylaktische Konzepte erfordern eine individualisierte Vorgehensweise mit detaillierter Diagnose des zugrundeliegenden genetischen Aortensyndroms inklusive Charakterisierung des Genotyps.
Abstract
Background
Genetic aortic syndromes are autosomal-dominantly heritable aneurysms of the thoracic aorta, which carry a high risk of aortic rupture or acute thoracic aortic dissection at young age.
Objectives
We introduce the reader to the principles of genetic diagnostics and the medical and surgical prevention of thoracic aortic dissection in patients with genetic aortic syndromes.
Methods
A cardiologist, a health economist, a patient representative, a heart surgeon, and a molecular geneticist teamed up to elucidate their perspective on major aspects of genetics and prevention of genetic aortic syndromes.
Results
Genetic aortic syndromes reflect a broad spectrum of diverse disease entities comprising the Marfan syndrome, the Loeys−Dietz syndrome or the vascular Ehlers−Danlos syndrome. The diagnosis of each respective disease entity requires combined assessment of phenotype and genotype information. A medical prevention of aortic complications such as dissection is mandatory although a curative therapy currently appears unlikely in humans. The single most important measure against acute aortic dissection is the preventive replacement of the aortic root, where valve preserving techniques appear preferable. Comprehensive prophylaxis including molecular diagnostics seem reasonable also from an economic point of view.
Discussion
Optimal prevention requires individualization of concepts, which entail a detailed diagnostic characterization of each specific genetic aortic syndrome including characterization of the genotype.
Literatur
Centers of Disease Control and Prevention (2007) WISQARS leading causes of death reports, 1999–2007. 20 leading causes of death, United States 2007, all races, both sexes. http://webappcdcgov/cgi-bin/brokerexe. Zugegriffen: 3. Nov. 2012
Howard DP, Banerjee A, Fairhead JF, Perkins J, Silver LE, Rothwell PM (2013) Population-based study of incidence and outcome of acute aortic dissection and premorbid risk factor control: 10-year results from the Oxford Vascular Study. Circulation 127:2031–2037
Hagan PG, Nienaber CA, Isselbacher EM et al (2000) The International Registry of Acute Aortic Dissection (IRAD): new insights into an old disease. JAMA 283:897–903
Januzzi JL, Isselbacher EM, Fattori R et al (2004) Characterizing the young patient with aortic dissection: results from the International Registry of Aortic Dissection (IRAD). J Am Coll Cardiol 43:665–669
Faivre L, Collod-Beroud G, Loeys BL et al (2007) Effect of mutation type and location on clinical outcome in 1013 probands with Marfan syndrome or related phenotypes and FBN1 mutations: an international study. Am J Hum Genet 81:454–466
Kuhne K, Keyser B, Groene EF et al (2012) FBN1 gene mutation characteristics and clinical features for the prediction of mitral valve disease progression. Int J Cardiol 168:953–959
Aydin A, Adsay BA, Sheikhzadeh S et al (2013) Observational cohort study of ventricular arrhythmia in adults with Marfan syndrome caused byFBN1 mutations. PLoS One 8:e81281
Sheikhzadeh S, Sondermann C, Rybczynski M et al (2013) Comprehensive analysis of dural ectasia in 150 patients with a causative FBN1 mutation. Clin Genet 86(3):238–245
Fattori R, Nienaber CA, Descovich B et al (1999) Importance of dural ectasia in phenotypic assessment of Marfan’s syndrome. Lancet 354:910–913
Sheikhzadeh S, Kade C, Keyser B et al (2012) Analysis of phenotype and genotype information for the diagnosis of Marfan syndrome. Clin Genet 82:240–247
Loeys BL, Schwarze U, Holm T et al (2006) Aneurysm syndromes caused by mutations in the TGF-beta receptor. N Engl J Med 355:788–798
Loeys BL, Dietz HC, Braverman AC et al (2010) The revised Ghent nosology for the Marfan syndrome. J Med Genet 47:476–485
Maccarrick G, Black JH 3rd, Bowdin S et al (2014) Loeys-Dietz syndrome: a primer for diagnosis and management. Genet Med 16(8):576–587
Milewicz DM, Guo DC, Tran-Fadulu V et al (2008) Genetic basis of thoracic aortic aneurysms and dissections: focus on smooth muscle cell contractile dysfunction. Annu Rev Genomics Hum Genet 9:283–302
Gillis E, Van Laer L, Loeys BL (2013) Genetics of thoracic aortic aneurysm: at the crossroad of transforming growth factor-β signaling and vascular smooth muscle cell contractility. Circulat Res 113:327–340
Aiuti A, Biasco L, Scaramuzza S et al (2013) Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 341:1233151
Hacein-Bey-Abina S, Hauer J, Lim A et al (2010) Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 363:355–364
Phylactou LA, Tsipouras P, Kilpatrick MW (1998) Hammerhead ribozymes targeted to the FBN1 mRNA can discriminate a single base mismatch between ribozyme and target. Biochem Biophys Res Commun 249:804–810
Yin H, Xue W, Chen S et al (2014) Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol 32:551–553
Zaradzki M, Arif R, Schwill S et al (2013) AP-1 decoy oligodeoxynucleotide inhibition of matrix metalloproteinase expression in vascular smooth muscle cells of fibrillin-1-deficient mgR/mgR-mice. Thorac Cardiovasc Surg 61:S23
Hurrelmann K, Klotz T, Haisch J (2004) Einführung: Krankheitsprävention und Gesundheitsförderung. In: Hurrelmann K, Altgeld T (Hrsg) Lehrbuch Prävention und Gesundheitsförderung. H. Huber, Bern, S 13–24
Faller H, Lang H (2010) Förderung und Erhaltung von Gesundheit: Prävention. In: Medizinische Psychologie und Soziologie. Springer, Heidelberg, S 311–337
Coron F, Rousseau T, Jondeau G et al (2012) What do French patients and geneticists think about prenatal and preimplantation diagnoses in Marfan syndrome? Prenat Diagn 32:1318–1323
Madelin R (2009) The voice of 12,000 patients. Experiences and expectations of rare disease patients on diagnosis and care in Europe. http://www.eurordis.org/IMG/pdf/voice_12000_patients/EURORDISCARE_FULLBOOKr.pdf. Zugegriffen: 21. Sept. 2014
Roll K (2012) The influence of regional health care structures on delay in diagnosis of rare diseases: the case of Marfan Syndrome. Health Policy 105:119–127
Arslan-Kirchner M, von Kodolitsch Y, Schmidtke J (2008) Genetische Diagnostik beim Marfan-Syndrom und verwandten Erkrankungen: Bedeutung des klinischen Managements. Dtsch Arztebl Int 105:483–491
von Kodolitsch Y, Baumgart D, Eggebrecht H et al (2003) Das akute Aortensyndrom. Dtsch Ärztebl 100:A326–A333
Sheikhzadeh S, Kusch ML, Rybczynski M et al (2012) A simple clinical model to estimate the probability of Marfan syndrome. QJM 105:527–535
Radke RM, Baumgartner H (2014) Diagnosis and treatment of Marfan syndrome: an update. Heart 100(17):1382–1391
Mueller GC, Stark V, Steiner K, Weil J, von Kodolitsch Y, Mir TS (2012) The Kid-Short Marfan Score (Kid-SMS) – An easy executable risk score for suspected paediatric Marfan patients. Acta Paediatr 102(2):e84–89
Matt P, Schoenhoff F, Habashi J et al (2009) Circulating transforming growth factor-beta in Marfan syndrome. Circulation 120:526–532
Hillebranda M, Millot N, Sheikhzadeh S et al (2014) Total serum transforming growth factor-beta 1 is elevated in the entire spectrum of genetic aortic syndromes. Clin Cardiol. doi:1002/clc.22320
Bartmann U (2007) Verhaltensmodifikation als Methode der Sozialen Arbeit: ein Leitfaden. DGVT, Tübingen
von Kodolitsch Y, Rybczynski M (2007) Marfan-Syndrom: Sport und Fitness. In: Marfan-Syndrom. Ein Ratgeber für Patienten, Angehörige und Betreuende. Steinkopff, Darmstadt
e. V. M-H (2006) Marfan-Syndrom: ein Ratgeber für Patienten, Angehörige und Betreuende. Steinkopff, Darmstadt
Neptune ER, Frischmeyer PA, Arking DE et al (2003) Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet 33:407–411
Ng CM, Cheng A, Myers LA et al (2004) TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. J Clin Invest 114:1586–1592
Cohn RD, van Erp C, Habashi JP et al (2007) Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nature Med 13:204–210
Habashi JP, Judge DP, Holm TM et al (2006) Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 312:117–121
Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, Dietz HC 3rd (2008) Angiotensin II blockade and aortic-root dilation in Marfan’s syndrome. N Engl J Med 358:2787–2795
Groenink M, den Hartog AW, Franken R et al (2013) Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. Eur Heart J 34(45):3491–3500
Hiratzka LF, Bakris GL, Beckman JA et al (2010) 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with Thoracic Aortic Disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation 121:e266–e369
Kallenbach K, Sundt TM, Marwick TH (2013) Aortic surgery for ascending aortic aneurysms under 5.0 cm in diameter in the presence of bicuspid aortic valve. JACC Cardiovasc Imaging 6:1321–1326
von Kodolitsch Y, Robinson PN, Berger J (2014) When should surgery be performed in Marfan syndrome and other connective tissue disorders to protect against type A dissection? In: Bonser R, Haverich A, Mascaro J, Pagano D (Hrsg) Controversies in Aortic Dissection and Aneurysmal Disease. Springer, London
Bentall HH (1987) Operation for ascending aortic aneurysm and aortic regurgitation–pathological influence on survival. Jpn J Surg 17:425–430
Sarsam MAI, Yacoub M (1993) Remodeling of the aortic valve anulus. J Thorac Cardiovasc Surg 105:435–438
David TE, Feindel CM (1992) An aortic valve-sparing operation for patients with aortic incompetence and aneurysm of the ascending aorta. J Thorac Cardiovasc Surg 103:617–621. (discussion 622)
Kallenbach K, Baraki H, Khaladj N et al (2007) Aortic valve-sparing operation in Marfan syndrome: what do we know after a decade? Ann Thorac Surg 83:S764–S768. (discussion S785–790)
Benedetto U, Melina G, Takkenberg JJM, Roscitano A, Angeloni E, Sinatra R (2011) Surgical management of aortic root disease in Marfan syndrome: a systematic review and meta-analysis. Heart (British Cardiac Society) 97:955–958
Achelrod D, Blankart CR, Linder R, von Kodolitsch Y, Stargardt T (2014) The economic impact of Marfan syndrome: a non-experimental, retrospective, population-based matched cohort study. Orphanet J Rare Dis 9:90
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
Prof. Dr. med. Y. von Kodolitsch, C.R. Blankart, M. Vogler, K. Kallenbach und P.N. Robinson erklären, dass kein Interessenkonflikt besteht.
Rights and permissions
About this article
Cite this article
von Kodolitsch, Y., Blankart, C., Vogler, M. et al. Genetik und Prävention am Beispiel genetischer Aortensyndrome (GAS) und des Marfan-Syndroms. Bundesgesundheitsbl. 58, 146–153 (2015). https://doi.org/10.1007/s00103-014-2093-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00103-014-2093-2